Moberg Pharma AB (Formerly known as Moberg Derma) Awarded $3 Million to Develop "Smart Neuro ICU" Medical Technology

AMBLER, Pa., Oct. 2, 2014 /PRNewswire/ -- Moberg Research, Inc. (Moberg, www.moberg.com) recently received a $3 million Rapid Innovation Fund grant from the United States Army to commercialize cutting-edge technology for patients with traumatic brain injuries (TBI). Moberg is creating a "Smart" Intensive Care Unit (ICU) as part of a global effort to improve treatment and outcomes for patients with brain injury.

Moberg's goal is to provide advanced neurological monitoring technology along with new tools that will help doctors make decisions based on the data they collect from patients. Moberg has decades of experience in medical device innovation and bioinformatics, which is the science of collecting and analyzing complex biological data. The company will leverage its existing commercial products and emerging technologies to provide doctors with "smart" decision-support algorithms. The resulting Smart ICU will provide healthcare professionals with detailed, precise patient information from admission to discharge.

New technologies are needed to treat neurological injuries, which are costly, complicated medical problems. Thus far, the complexity of the brain's interconnected systems has prevented scientists from developing successful pharmaceutical interventions and therapies to treat TBI. Often, doctors are unable to predict outcomes for TBI patients. Even when two patients have similar injuries, their outcomes may differ greatly due to unidentified underlying mechanisms, including genetics, medical history and prior injury.

Now, medical professionals are rethinking their approach to TBI research. New international studies, CENTER-TBI and TRACK-TBI, aim to give doctors a deeper understanding of brain injury and enable them to better diagnose and care for TBI patients. During these studies, researchers will use medical devices provided by Moberg to monitor patients' statuses. Data collected will be shared amongst all researchers to accelerate analysis.

Moberg plans to incorporate findings from the international TBI studies into its Smart ICU project. During the second year of the project, Moberg will create Smart ICU test sites at selected hospitals, including Yale-New Haven Hospital, San Francisco General Hospital, and Ronald Reagan UCLA Medical Center. At these locations, doctors and nurses will evaluate how well the technology supports their ability to detect changes in patients' conditions and make timely, life-saving care decisions.

Moberg (Moberg Research, www.moberg.com) is a privately owned medical device manufacturing company specializing in neurological patient monitoring solutions for acute care. Founded in 1998, Moberg is located in Ambler, PA in the greater Philadelphia area.

SOURCE Moberg Research, Inc.